Corinne Jenkins
Stock Analyst at Goldman Sachs
(1.66)
# 3,419
Out of 5,090 analysts
60
Total ratings
43.9%
Success rate
-5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corinne Jenkins
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IDYA IDEAYA Biosciences | Maintains: Neutral | $27 → $30 | $35.87 | -16.36% | 6 | Oct 21, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $157 → $139 | $104.60 | +32.89% | 10 | Oct 17, 2025 | |
| ROIV Roivant Sciences | Maintains: Buy | $20 → $24 | $20.97 | +14.45% | 6 | Sep 18, 2025 | |
| GERN Geron | Reinstates: Sell | $1 | $1.31 | -23.66% | 4 | Jul 10, 2025 | |
| TGTX TG Therapeutics | Maintains: Neutral | $20 → $22 | $30.76 | -28.48% | 8 | Nov 5, 2024 | |
| FULC Fulcrum Therapeutics | Upgrades: Buy | $6 → $15 | $8.90 | +68.54% | 2 | May 14, 2024 | |
| ALT Altimmune | Reinstates: Neutral | $13 | $5.24 | +148.09% | 3 | Jan 24, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Sell | $25 → $28 | $39.83 | -29.70% | 7 | Jan 9, 2024 | |
| BTAI BioXcel Therapeutics | Maintains: Neutral | $192 → $64 | $2.07 | +2,991.79% | 6 | Aug 15, 2023 | |
| RAPT RAPT Therapeutics | Maintains: Buy | $216 → $184 | $34.47 | +433.87% | 2 | Mar 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $21 | $2.92 | +619.18% | 2 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $14 | $29.36 | -52.32% | 2 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $160 | $3.90 | +4,002.56% | 2 | Dec 15, 2021 |
IDEAYA Biosciences
Oct 21, 2025
Maintains: Neutral
Price Target: $27 → $30
Current: $35.87
Upside: -16.36%
Rhythm Pharmaceuticals
Oct 17, 2025
Maintains: Buy
Price Target: $157 → $139
Current: $104.60
Upside: +32.89%
Roivant Sciences
Sep 18, 2025
Maintains: Buy
Price Target: $20 → $24
Current: $20.97
Upside: +14.45%
Geron
Jul 10, 2025
Reinstates: Sell
Price Target: $1
Current: $1.31
Upside: -23.66%
TG Therapeutics
Nov 5, 2024
Maintains: Neutral
Price Target: $20 → $22
Current: $30.76
Upside: -28.48%
Fulcrum Therapeutics
May 14, 2024
Upgrades: Buy
Price Target: $6 → $15
Current: $8.90
Upside: +68.54%
Altimmune
Jan 24, 2024
Reinstates: Neutral
Price Target: $13
Current: $5.24
Upside: +148.09%
Harmony Biosciences Holdings
Jan 9, 2024
Maintains: Sell
Price Target: $25 → $28
Current: $39.83
Upside: -29.70%
BioXcel Therapeutics
Aug 15, 2023
Maintains: Neutral
Price Target: $192 → $64
Current: $2.07
Upside: +2,991.79%
RAPT Therapeutics
Mar 15, 2023
Maintains: Buy
Price Target: $216 → $184
Current: $34.47
Upside: +433.87%
Mar 7, 2023
Maintains: Buy
Price Target: $25 → $21
Current: $2.92
Upside: +619.18%
Dec 20, 2022
Maintains: Buy
Price Target: $9 → $14
Current: $29.36
Upside: -52.32%
Dec 15, 2021
Initiates: Neutral
Price Target: $160
Current: $3.90
Upside: +4,002.56%